Logo image of MREO

MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MREO - US5894921072 - ADR

2.0599 USD
+0.14 (+7.29%)
Last: 12/19/2025, 1:59:00 PM
Fundamental Rating

2

Overall MREO gets a fundamental rating of 2 out of 10. We evaluated MREO against 529 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MREO as it has an excellent financial health rating, but there are worries on the profitability. MREO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MREO has reported negative net income.
In the past year MREO has reported a negative cash flow from operations.
MREO had negative earnings in 4 of the past 5 years.
In the past 5 years MREO always reported negative operating cash flow.
MREO Yearly Net Income VS EBIT VS OCF VS FCFMREO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

MREO has a Return On Assets of -77.77%. This is in the lower half of the industry: MREO underperforms 65.97% of its industry peers.
MREO has a Return On Equity (-89.46%) which is in line with its industry peers.
Industry RankSector Rank
ROA -77.77%
ROE -89.46%
ROIC N/A
ROA(3y)-46.82%
ROA(5y)-74.73%
ROE(3y)-61.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MREO Yearly ROA, ROE, ROICMREO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

MREO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MREO Yearly Profit, Operating, Gross MarginsMREO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

7

2. Health

2.1 Basic Checks

MREO does not have a ROIC to compare to the WACC, probably because it is not profitable.
MREO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MREO has been increased compared to 5 years ago.
The debt/assets ratio for MREO is higher compared to a year ago.
MREO Yearly Shares OutstandingMREO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
MREO Yearly Total Debt VS Total AssetsMREO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 11.45 indicates that MREO is not in any danger for bankruptcy at the moment.
MREO has a better Altman-Z score (11.45) than 83.55% of its industry peers.
MREO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.45
ROIC/WACCN/A
WACC9.26%
MREO Yearly LT Debt VS Equity VS FCFMREO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 8.71 indicates that MREO has no problem at all paying its short term obligations.
MREO has a better Current ratio (8.71) than 76.94% of its industry peers.
A Quick Ratio of 8.71 indicates that MREO has no problem at all paying its short term obligations.
With a decent Quick ratio value of 8.71, MREO is doing good in the industry, outperforming 76.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.71
Quick Ratio 8.71
MREO Yearly Current Assets VS Current LiabilitesMREO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

MREO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.56%, which is quite impressive.
MREO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.00%.
EPS 1Y (TTM)36.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
Revenue 1Y (TTM)-95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 29.98% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-3.75%
EPS Next 2Y12.48%
EPS Next 3Y36.06%
EPS Next 5Y29.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MREO Yearly Revenue VS EstimatesMREO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
MREO Yearly EPS VS EstimatesMREO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 -0.2 0.4 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MREO. In the last year negative earnings were reported.
Also next year MREO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MREO Price Earnings VS Forward Price EarningsMREO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MREO Per share dataMREO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

MREO's earnings are expected to grow with 36.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.48%
EPS Next 3Y36.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MREO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MEREO BIOPHARMA GROUP PL-ADR

NASDAQ:MREO (12/19/2025, 1:59:00 PM)

2.0599

+0.14 (+7.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners12.82%
Inst Owner Change1.56%
Ins Owners0.17%
Ins Owner Change0%
Market Cap327.80M
Revenue(TTM)500.00K
Net Income(TTM)-41.69M
Analysts88
Price Target7.14 (246.62%)
Short Float %29.33%
Short Ratio5.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-219.99%
Min EPS beat(2)-499.63%
Max EPS beat(2)59.64%
EPS beat(4)1
Avg EPS beat(4)-481.7%
Min EPS beat(4)-1246.69%
Max EPS beat(4)59.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-120%
EPS NQ rev (3m)-120%
EPS NY rev (1m)5.26%
EPS NY rev (3m)5.26%
Revenue NQ rev (1m)-35.14%
Revenue NQ rev (3m)-35.14%
Revenue NY rev (1m)-39.49%
Revenue NY rev (3m)-39.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 655.59
P/FCF N/A
P/OCF N/A
P/B 7.03
P/tB 7.13
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.29
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -77.77%
ROE -89.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.82%
ROA(5y)-74.73%
ROE(3y)-61.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.39%
Cap/Sales 64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.71
Quick Ratio 8.71
Altman-Z 11.45
F-Score3
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)35.04%
Cap/Depr(5y)37.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
EPS Next Y-3.75%
EPS Next 2Y12.48%
EPS Next 3Y36.06%
EPS Next 5Y29.98%
Revenue 1Y (TTM)-95%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.11%
EBIT Next 3Y36.53%
EBIT Next 5YN/A
FCF growth 1Y-55.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.38%
OCF growth 3YN/A
OCF growth 5YN/A

MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ

What is the ChartMill fundamental rating of MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MREO.


What is the valuation status for MREO stock?

ChartMill assigns a valuation rating of 1 / 10 to MEREO BIOPHARMA GROUP PL-ADR (MREO). This can be considered as Overvalued.


Can you provide the profitability details for MEREO BIOPHARMA GROUP PL-ADR?

MEREO BIOPHARMA GROUP PL-ADR (MREO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for MREO stock?

The Earnings per Share (EPS) of MEREO BIOPHARMA GROUP PL-ADR (MREO) is expected to decline by -3.75% in the next year.